Allergan PLC said early Thursday that the Food and Drug Administration has approved its cream for persistent facial redness in adults. An estimated 16 million Americans have rosacea, which most commonly manifests as persistent facial redness and can be triggered by sun exposure, stress, exercise and more. The treatment, Rhofade, will be available commercially starting in May, Allergan said. Allergan shares, which were up a scant 1.0% in pre-market trade, have dropped 5.4% over the last three months, compared with a 6.0% rise in the S&P 500 .
Continue Reading Below
Copyright © 2017 MarketWatch, Inc.